SELECT trial: difference between revisions
Diff·revision 6 → 7·07:34, 15 Oct 2024
Difference between revision 6 and revision 7 of SELECT trial. 3 lines changed; the page grew by 454 bytes.
| Revision 6 — 16:58, 6 Oct 2024 CiteBot (talk) bot: expand PMID to full citation 2,328 bytes +28 | Revision 7 — 07:34, 15 Oct 2024 KPV_Kester (talk) split overlong sentence 2,782 bytes +454 | ||
|---|---|---|---|
| 18 | This is an important design feature: the trial tested semaglutide added to background therapy including statins and antiplatelet agents in a majority of participants, so the observed effect is incremental to contemporary secondary prevention rather than a comparison against nothing. | 18 | This is an important design feature: the trial tested semaglutide added to background therapy including statins and antiplatelet agents in a majority of participants, so the observed effect is incremental to contemporary secondary prevention rather than a comparison against nothing. |
| 19 | 19 | ||
| + | 20 | Mean weight reduction on active treatment was about 9.4%, less than the 14.9% seen in [[STEP trial programme|STEP 1]] — a reminder that trial populations differ and that an effect size does not transfer between them.{{r|wilding2021}} | |
| + | 21 | ||
| 20 | == References == | 22 | == References == |
| 21 | {{reflist}} | 23 | {{reflist}} |
| 22 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> | 24 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> |
| 23 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). PMID 27633186.</ref> | 25 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). PMID 27633186.</ref> |
| + | 26 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | |
| 24 | 27 | ||
| 25 | {{DEFAULTSORT:SELECT trial}} | 28 | {{DEFAULTSORT:SELECT trial}} |